Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

Condition:   Cervical Cancer Intervention:   Combination Product: Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy Sponsor:   Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

Condition:   Cervical Cancer Intervention:   Drug: AK105 and anlotinib Sponsor:   The First Affiliated Hospital of Zhengzhou University Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Vaccine. 2021 Nov 26:S0264-410X(21)01466-3. doi: 10.1016/j.vaccine.2021.11.021. Online ahead of print.ABSTRACTThe introduction of the Human papillomavirus (HPV) vaccine has shown potential to not only prevent cervical cancer but also drive adolescents' access to other health care services, even in low-income countries. Few studies have been conducted to date to identify best practices and estimate the acceptance, operational challenges and benefits of including broader adolescent health interventions into immunization efforts, knowledge which is essential to supporting widespread integration. In this paper we review the ef...
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
AbstractKey ContentCervical cancer is the commonest gynaecological malignancy diagnosed in pregnancy.Cancer symptoms may mimic complications of pregnancy, thus delaying diagnosis.Staging of cervical cancer in pregnancy is essential to determine an individual management plan.Treatment of cervical cancer in pregnancy is complex and depends on the stage of cancer and the gestation of the pregnancy.Involvement of a multidisciplinary team is essential in the care of a woman with cervical cancer in pregnancy.Learning ObjectivesTo understand how to diagnose, stage and treat cervical cancer in pregnancy.To know the risks to the fe...
Source: The Obstetrician and Gynaecologist - Category: OBGYN Authors: Tags: REVIEWS Source Type: research
Cancer is a major concern in older people, with almost 50% of new diagnoses and 70% of cancer-related deaths in individuals older than 65 years [1,2]. Cervical cancer (CC), mostly human papillomavirus (HPV)-induced, ranks fourth for both incidence and mortality in women worldwide [3]. There are two peaks of incidence, the first between 30 and 39 years of age and the second between 60 and 69 years. Almost 1 in 4 cases are diagnosed after the age of 60 years [4].
Source: Maturitas - Category: Primary Care Authors: Tags: Original Article Source Type: research
ConclusionHPV16, 18, and 45 should receive special attention for molecular diagnostic algorithms during CC prevention programs for HIV+ women from sub-Saharan Africa. HPV35 may have a high potential to induce HSIL in women living with HIV, but less potential to cause cervical cancer in single-type infections.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The purpose of this integrative literature review was to appraise studies conducted worldwide using misoprostol and estradiol in converting Type 3 transformation zone (TZ) of the cervix into Types 1 or 2 and to assess which regimen could be more feasible in low-and-middle-income countries (LMICs). We reviewed the English language literature for peer-reviewed studies that evaluated strategies to convert Type 3 TZs to Types 1 or 2 for cervical cancer screening. Web of Science and PubMed searches were performed up to July 2020.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Source Type: research
Modern Pathology, Published online: 30 November 2021; doi:10.1038/s41379-021-00979-4Expression of B7 family checkpoint proteins in cervical cancer
Source: Modern Pathology - Category: Pathology Authors: Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
This study applied a cross sectional design by collecting data from a convenient sample of 200 women between 20 and 70 years of age in health and public centers in Jordan. Data was then analyzed using the descriptive statistical tools of SPSS, version 21. The findings revealed that 55.5% of the participants had no information about the Pap smear, and 75% did not know the risk factors. Moreover, 50% of the sample did not know where to take the test, and 50% reported a lack of encouragement from the husband to undertake the test. More than half of the participants (56.5%) expressed fear that cervical screening woul...
Source: International Journal of Human Rights in Healthcare - Category: International Medicine & Public Health Authors: Source Type: research
More evidence supports the impact of HPV vaccination programs on cervical cancer rates and deaths.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Cervical Cancer | Hospitals | Research